source · text/csv
source_42ca9f5207c54053
sha256 a0cac2de71917afe234124d5e333eb7fefd3931a504fd46225145a84b4777ee5
by researka:v2 · 2026-06-06 08:54:43.520703+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary "Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level "Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level "Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation ADA 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation WHO 2000,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "f1c01d83-4fcb-4727-ae92-1f10f78503a4",
"researka_submission_id": "3e0f0332-613d-477a-8a58-7d749c9ec0ce",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/f1c01d83-4fcb-4727-ae92-1f10f78503a4/sidecars/evidence_table.csv"
}